90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2
- PMID: 30052509
- DOI: 10.1016/S2352-3018(18)30094-8
90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2
Abstract
Distinct from HIV-1 and often neglected in the global campaign to end the AIDS epidemic, HIV-2 presents unique and underappreciated challenges in diagnosis, clinical care, antiretroviral therapy (ART), and HIV programmatic management. Here, we review the epidemiology and natural history of HIV-2, diagnostics and algorithms for accurately diagnosing and differentiating HIV-2 from HIV-1, the unique features of HIV-2 ART and drug resistance, and the clinical care and management of patients infected with HIV-2 in both developed and resource-limited settings. Ultimately, further research is needed to address the gaps in our knowledge of HIV-2 infection, increased resources are needed to specifically target HIV-2 as part of the UNAIDS/WHO 90-90-90 campaign to end AIDS, and increased determination is needed to better advocate for inclusion of people living with HIV-2 in global HIV/AIDS initiatives.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Retention of HIV-Infected Children in the First 12 Months of Anti-Retroviral Therapy and Predictors of Attrition in Resource Limited Settings: A Systematic Review.PLoS One. 2016 Jun 9;11(6):e0156506. doi: 10.1371/journal.pone.0156506. eCollection 2016. PLoS One. 2016. PMID: 27280404 Free PMC article. Review.
-
Ending the epidemic: Critical role of primary HIV infection.Neth J Med. 2017 Oct;75(8):321-327. Neth J Med. 2017. PMID: 29219825 Review.
-
Management of HIV in resource limited settings.Curr Opin Infect Dis. 2009 Oct;22(5):464-70. doi: 10.1097/QCO.0b013e3283308fe2. Curr Opin Infect Dis. 2009. PMID: 19730283 Review.
-
[Optimizing resources to reduce costs to determine HIV viral load in limited resources settings].Biomedica. 2017 Dec 1;37(4):460-465. doi: 10.7705/biomedica.v37i4.3318. Biomedica. 2017. PMID: 29373766 Spanish.
-
HIV treatment scale-up: a critical step to controlling HIV epidemic in a resource-limited country.Public Health. 2018 Nov;164:68-71. doi: 10.1016/j.puhe.2018.07.016. Epub 2018 Sep 8. Public Health. 2018. PMID: 30199742
Cited by
-
Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2.Viruses. 2024 Oct 13;16(10):1607. doi: 10.3390/v16101607. Viruses. 2024. PMID: 39459940 Free PMC article.
-
Combating antimicrobial resistance in malaria, HIV and tuberculosis.Nat Rev Drug Discov. 2024 Jun;23(6):461-479. doi: 10.1038/s41573-024-00933-4. Epub 2024 May 15. Nat Rev Drug Discov. 2024. PMID: 38750260 Review.
-
HIV-2 mediated effects on target and bystander cells induce plasma proteome remodeling.iScience. 2024 Feb 28;27(4):109344. doi: 10.1016/j.isci.2024.109344. eCollection 2024 Apr 19. iScience. 2024. PMID: 38500818 Free PMC article.
-
Replicative fitness and pathogenicity of primate lentiviruses in lymphoid tissue, primary human and chimpanzee cells: relation to possible jumps to humans.EBioMedicine. 2024 Feb;100:104965. doi: 10.1016/j.ebiom.2023.104965. Epub 2024 Jan 12. EBioMedicine. 2024. PMID: 38215691 Free PMC article.
-
Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.J Infect Dis. 2024 May 15;229(5):1290-1294. doi: 10.1093/infdis/jiad562. J Infect Dis. 2024. PMID: 38060982
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

